precise role, if any, of the virus in the establishment and maintenance of this disease and how various cofactors may interact with EBV to bring about the onset of the neoplasm. This meeting reviewed the current state of our understanding of some of the molecular biological processes relevant to the genesis, diagnosis and prevention of a cancer which afflicts several thousand people per year in southeast Asia and many others worldwide.
Carcinogenesis is currently thought to be a multifactorial process and the virologists' enthusiasm was tempered by some epidemiological insights into the potential involvement of other agents. Nick Day (Cambridge) showed that a significant genetic predisposition to NPC is related to certain HLA types, in particular A2, B17, and BW46. Interestingly the last appears to be present only in Chinese populations. Guy de The (Lyon) pointed out that ethnic differences in similar geographical regions (eg Southern China) are associated with marked variations in the frequency of NPC and that these could be attributable to differences in food habits. Relatively high levels of nitrosamines and mutagens are found in some of the staple foods of high risk areas. Extracts from Chinese dried salted fish or some traditional food from Tunisia (another high risk area) act The importance of early diagnosis in terms of patient Br. J. Cancer (1988), 57, 233-234 kl---" The Macmillan Press Ltd., 1988 survival was emphasised by de The, Wolf and Mei Ying Liu (Taipei). The diagnostic value of elevated IgA antibodies against EBV early antigen and virus capsid antigen was discussed by the first two speakers whilst Liu showed more specifically that antibodies against the EBV DNase had a predictive value in diagnosing NPC.
The need for a vaccine against EBV as a means of preventing NPC was introduced by Anthony Epstein (Oxford) and was followed by descriptions of the progress towards this goal. The use of the EBV glycoprotein gp340 which will induce EBV-neutralising antibodies was chronicled by Andrew Morgan (Bristol). Using the cottontop tamarin as an experimental model encouraging results have been obtained by presenting this glycoprotein to the animals using ISCOMS, with a muramyl dipeptide or expressed in a vaccinia virus recombinant. Ling Chan (London) described how the EBV homologue of the HSV glycoprotein B may be useful as a basis for a vaccine whilst Mike Mackett (Manchester) suggested that other predicted EBV glycoprotein genes incorporated into vaccinia virus either alone or in concert with gp340 may be useful.
Many people felt that a vaccine against EBV should, if it is to be effective against NPC, prevent primary infection and establishment of latency by the virus possibly by stimulating anti-EBV IgA. In the experiments on prevention of EBVinduced lymphoma development in cottontop tamarins it was not clear whether these desiderata had been obtained. Nina Wedderburn (London) showed that common marmosets could be infected orally by EBV and exhibited serum responses similar to that seen in humans suffering from infectious mononucleosis. Thus this animal may be an appropriate model to use as a test for prevention of primary infection.
Alan Rickinson (Birmingham) pointed out that knowledge of the immunology of the normal EBV infection was rather primitive and suggested that an effective vaccine may require the generation of cytotoxic T cells directed against processed forms of EBV latent proteins. David Tyrrell (Salisbury) reviewed the vaccine field and felt there is reason for cautious optimism that a vaccine will succeed but clearly much remains to be understood both on the genesis of NPC and as to how to deliver the appropriate antigens. 
